News

CLINICAL OMICS | 02.11.20

Moving the Diagnostics Needle for Personalized Care

Clinical OMICs featured comments that Eric Schadt, Ph.D., Founder and CEO of Sema4, made in a recent panel discussion titled “Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine.” The panel was chaired and moderated by Michael Pellini, M.D., a member of Sema4’s Board of Directors. At Sema4, “the focus is on developing actionable data from patients, while also keeping the patient in control of their own health data,” shared Eric. Read the full article below by Chris Anderson, Editor-in-Chief at Clinical Omics.
READ MORE
SEMA4 PRESS RELEASE | 11.14.19

Sema4 Appoints Biotech Leader Joel Sendek as Chief Financial Officer

Sema4 announces the appointment of Joel Sendek as Chief Financial Officer. Mr. Sendek has more than 25 years of financial leadership experience in the pharmaceutical and biotechnology sector, including overseeing the successful initial public offerings at his last two companies.
READ MORE
SEMA4 PRESS RELEASE | 10.11.19

Sema4 Applies Data-Driven Approach to Expanded Carrier Screening

Sema4 Applies Data-Driven Approach to Expanded Carrier Screening, and Will Soon Utilize Exome Sequencing for Genetic Testing Powered by the Centrellis™ Health Intelligence Platform, Sema4’s Expanded Carrier Screen with Personalized Residual Risk Will Help Inform Pregnancy Planning Decisions.
READ MORE
GENOMEWEB | 08.29.19

Sema4 Lands New Investors, Continues to Expand

Sema4 has landed its first outside investment, allowing it to continue its rapid growth. Sema4 updated its investors webpage to include five new entities: private equity behemoth Blackstone; venture capital funds Section 32, OakHC/FT, and Decheng Capital; and Connecticut Innovations, the state’s quasi-public investment agency.
READ MORE
SEMA4 PRESS RELEASE | 08.01.19

Sema4 Announces Location of its Second Connecticut Lab

Sema4 announces location of its second Connecticut Lab as part of the company’s commitment to the state’s biotech industry. The new 70,000 square foot facility in Stamford will soon be home to 300+ employees. Governor Ned Lamont and U.S. Representative Jim Himes joined a ceremony on August 1st to commence construction.
READ MORE

SEMA4 PRESS RELEASE | 05.30.19

Sema4 Launches New Genomic Testing and Digital Tools for Use in Oncology

Sema4, a patient-centered health intelligence company, today announced the launch of several new genomic testing services and digital tools to help oncologists deliver on the promise of precision medicine. Together, these products provide a comprehensive approach that can be used throughout a patient’s journey, from assessing risk to analyzing cancer and monitoring in remission. Demonstrations of the products will be available at Sema4’s booth (#7140) at the American Society for Clinical Oncology 2019 Annual Meeting taking place in Chicago from May 31 to June 4.
READ MORE

FORBES | 04.08.19

Mother’s Day Gift Guide: Sema4 Natalis Newborn Screen, excellent idea for new moms

“When babies are born, hospitals screen for some genetic conditions, but would more in-depth testing provide greater peace of mind? New moms might appreciate the gift of at-home DNA screening through Sema4. The kit includes a simple cheek swab to collect a sample — no finger prick or blood draws needed!”
READ MORE
WIRED | 03.27.19

Sema4 provides women more personalized recommendations for accessing care

“For Sema4, reproductive genetic test are the foundation of an even more grandiose undertaking – collecting a universe of biodata so big and so powerful that it will blot out the one-size-fits-all model of care that has for so long dictated how doctors treat their patients…”
READ MORE
STAMFORD ADVOCATE | 12.6.18

Sema4 co-leads Asthma study with Sanofi

“Health care testing company Sema4 announced this week it would help launch an asthma study that aims to advance diagnoses and treatments of the chronic respiratory disease. Sema4, the Mount Sinai Health System and Sanofi are partnering on the five-year assessment of nearly 1,200 asthma patients in the U.S. to better understand the source of asthma attacks, the disease’s varying impact on patients, and the potential of certain therapies. For Sema4, the findings would help to develop asthma tests…”
READ MORE
FIERCE BIOTECH | 12.5.18

Sanofi, Sema4 Launch 5-Year, Real-World Digital Asthma Study

“Sanofi and Sema4 have launched a five-year longitudinal study of nearly 1,200 asthma patients, with plans to incorporate digital tools to develop a better understanding of the disease. Alongside collections of clinical, genomic and environmental data, it will employ connected inhalers to track how the disease affects some individuals differently than others, in what Sanofi describes as one of the largest studies of its kind…”
READ MORE